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Substantial evidence collected from clinical data and ex-
perimental studies has indicated that CNS is not spared
from diabetes complications. Impairments in CNS function
are well documented in both type 1 and type 2 diabetic
patients as well as in various animal models of diabetes,
in terms of alterations in cognition, neuropsychology, neu-
robehavior, electrophysiology, structure, neurochemistry
and apoptotic activities. These data suggest that primary
diabetic encephalopathy exists as a deﬁnable diabetic com-
plication. The mechanisms underlying this CNS complica-
tion are not clear. Experimental studies have suggested that
neuronal apoptosis may play an important role in neuronal
loss and impaired cognitive function. In diabetes multiple
factorsareresponsibleforneuronalapoptosis,suchasaper-
turbed IGF system, hyperglycemia and the aging process
itself. Recent data suggest that insulin/C-peptide deﬁciency
may exert an eminent role. Administration of C-peptide
partially corrects the perturbed IGF system in the brain
and prevents neuronal apoptosis in hippocampus of type 1
diabetes. In neuroblastoma SH-SY5Y cells C-peptide pro-
videsadose-dependentstimulationoncellproliferationand
an anti-apoptotic effect as well. These studies provide a ba-
sis for administration of C-peptide as a potentially effective
therapy for type 1 diabetes.
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INTRODUCTION
Diabetes is a common metabolic disorder affecting many
systems, including muscle, retina, kidney, blood vessels (small
and large vessels), and the nervous system. With respect to
the nervous system, the peripheral nervous system (PNS) has
traditionally been considered as the sole nervous system com-
plicationindiabetes,whereasthecentralnervoussystem(CNS)
was believed to be spared from diabetes. However, recent stud-
ies have suggested that diabetes causes primary as well as sec-
ondary impairments in CNS function. In this review, we will
describe the CNS complications occurring in diabetic patients
and experimental models of diabetes. Several possible mech-
anisms will be discussed, although we will focus on neuronal
apoptosis and CNS dysfunction.
CNS COMPLICATIONS IN DIABETES
Clinical Studies
Diabetes-related cognitive dysfunction has been recognized
since the early 1920s in the medical literature (Miles and Root,
1922). Subsequently, many studies of both type 1 and type 2
diabetic subjects have found that diabetes mellitus is associ-
ated with a series of neurobehavioral or neuropsychological
changes. “Diabetic encephalopathy” could, therefore, be in-
cluded as one of the complications associated with diabetes.
CNS Complications in Type 1 Diabetic Patients
Impairments in learning, memory, problem solving, and
mental and motor speed are more common in type 1 diabetic
patients than in the general population (McCarthy et al., 2002;
Ryan, 1988; Ryan and Williams, 1993; Ryan et al., 1993).
The cognitive impairments can be severe in rare cases (Deary
et al., 1993; Gold et al., 1994), but is in most cases modest. The
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variationinseverityandpatternofimpairmentmaybeduetothe
subtle nature of the defects and variation in the diabetic pop-
ulations selected for study, the patient number in each study,
the psychological tests employed, and variations in glycemic
controls among individual studies. A lower Wechsler Intelli-
gence Scale for Children—Revised (WISC-R) performance IQ
was found in type 1 diabetic children with disease onset at
less than 7 years of age and disease duration greater than or
equalto5years(HolmesandRichman,1985).Diabeticpatients
suffered from signiﬁcantly more introversive symptoms than
their healthy counterparts, especially with respect to somatic
symptoms, sleeping disturbances, compulsions, and depressive
moods (Blanz et al., 1993; Kovacs et al., 1997; Lustman et al.,
1988;Popkinetal.,1988).Thesestudiesthusindicateimpaired
CNS function in type 1 diabetes.
The neuropsychological changes are often accompanied
withobjectiveelectrophysiological,structural,andneurochem-
ical abnormalities. In electrophysiological studies, measure-
ments of latencies of evoked potentials have been widely
used to examine the functional integrities of the CNS in di-
abetic patients (Di Mario et al., 1995). Delayed conduction
velocity and data-processing time in the CNS were demon-
stratedintype1diabeticpatients,includingbrainstemauditory-
evoked potential, somatosensory-evoked potentials, visual-
evoked potentials, and motor-evoked potentials (Comi, 1997;
Cracco et al., 1984;Harkinsetal.,1985;Pietravalleetal.,1993;
Uberall et al., 1996; Verrotti et al., 2000). The latency of the
P100 wave of the visual-evoked potential, which is believed to
begeneratedinthevisualcortex,isincreasedindiabeticpatients
(ParisiandUccioli,2001;Ziegleretal.,1994).Theevent-related
(P300) potential is an objective measure of cognitive function
(Madl et al., 1994; Picton, 1992). Several studies have shown
thatP300latency,aneurophysiologicalcorrelateofinformation
processing, such as stimulus evaluation, alertness, and memory
updating (Kramer et al., 1998), is increased in diabetic patients
(Kramer et al., 1998; Pozzessere et al., 1991; Uberall et al.,
1996), indicating an impairment of higher brain functions.
In terms of structural changes, several abnormalities have
been described in type 1 diabetic patients, such as diffuse and
local degenerative changes of cerebral cortex (Reske-Nielsen
andLundbaek,1964;Reske-Nielsenetal.,1965),neuronalloss,
demyelinationandgliosis,andinfarctionsecondarytomicroan-
giopathy (DeJong, 1977). Magnetic resonance imaging and
computed tomography have shown that widened sulci and/or
enlarged lateral ventricles (Araki et al., 1994; Lunetta et al.,
1994; Perros et al., 1997) and increased occurrence of white
matter hyperintensities (Araki et al., 1994; Perros et al., 1997)
are more pronounced in diabetic patients than in age-matched
control subjects. These studies indicate structural changes in
CNS of diabetes.
Because hypoglycemia itself can cause brain damages (de
Courten-Myers et al., 2000; Vannucci and Vannucci, 2001;
Yager, 2002), it remains controversial as to whether the above
CNS abnormalities are caused by diabetes per se (primary) or
are the result of hypoglycemic episodes (secondary), which oc-
cur frequently in type 1 diabetic patients receiving intensive
insulin treatment. Recent studies have shown that a duration-
dependentdeclineincognitivefunctionoccursintype1diabetic
patients without hypoglycemic episodes (Kramer et al., 1998),
and that impaired intellectual and cognitive development occur
in type 1 diabetic children, who have not experienced hypo-
glycemic episodes (Schoenle et al., 2002). These latter impair-
ments correlate with diagnosis at young age, male sex, and
metabolic status at time of diagnosis. Therefore, CNS compli-
cations seem to be impacted by diabetes itself without imple-
menting hypoglycemic episodes as a causative mechanism and
hence being primary.
In summary, evidence obtained from pathologic, physio-
logic, psychologic, and behavioral studies point toward a “pri-
mary diabetic encephalopathy” in type 1 diabetes.
CNS Complications in Type 2 Diabetic Patients
Neuropsychologic studies in type 2 diabetes patients have
shown more consistent results compared to type 1 diabetes
patients. Cognitive deﬁcits (Gradman et al., 1993; Perlmuter
et al., 1984; Ryan and Geckle, 2000a; Strachan et al., 1997;
Tun et al., 1990; Worrall et al., 1993) and poor performance
in abstract reasoning and complex psychomotor functioning
(Reaven et al., 1990) occur in type 2 diabetes. Complex cog-
nitive functions, as demonstrated by complex cognitive tasks
requiringstorageandretrievalofnewinformation,areaffected,
whereas performances of less demanding tasks, such as imme-
diate memory and simple reaction time, are not signiﬁcantly
altered (Tun et al., 1990). Electrophysiological studies have
demonstrated delayed CNS conduction velocity (Donald et al.,
1984; Varsik et al., 2001; Verrotti et al., 2000) and increased
latency of P100 (Ziegler et al., 1994). Several studies demon-
strate that P300 latency is increased in type 2 diabetic patients
(Dey et al., 1997; Kurita et al., 1995; Mochizuki et al., 1998;
Mooradian et al., 1988), indicating an impairment of higher
brain function. Recently, increased blood-brain barrier (BBB)
permeability in type 2 diabetes was demonstrated by magnetic
resonanceimagingwhenintravenousadministrationofgadolin-
ium diethylenetriamine pentaacetic acid (Gd-DTPA) was used
to identify BBB permeability, suggesting that loss of BBB in-
tegrity may play a role in CNS dysfunction in diabetes (Starr
et al., 2003). In the All Wales Research into Elderly (AWARE)
DiabetesStudy,elderlytype2diabeticpatientsdisplayedsignif-
icant excess of cognitive dysfunction associated with a poorer
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no signiﬁcant impairments in learning, memory and problem-
solvingskillswerefoundinmiddle-agedtype2diabeticpatients
comparedtocontrolsubjects(RyanandGeckle,2000b).Infact,
few studies have been conducted regarding cognitive deﬁcits in
middle-aged type 2 diabetic patients, among which the largest
patientnumberwas80type2diabeticpatientsversus81nondi-
abeticcontrols(Loweetal.,1994).Therefore,morestudieswith
large number of patients are needed in determining cognitive
function in middle-aged type 2 diabetes. The current thought
is that learning and memory dysfunction are more prominent
in elderly type 2 diabetic subjects (Ryan and Geckle, 2000a).
As to whether this is due to a potentiation of the normal ag-
ing process by superimposed diabetes or a function of diabetes
duration alone is not settled.
The etiology of cognitive dysfunction in type 2 diabetes is
not fully understood. It is likely that cognitive impairments are
caused by an interaction between metabolic abnormalities in-
trinsic to diabetes and diabetes-speciﬁc complications. After
all, the higher frequency of cerebral stroke in type 2 diabetes
may be associated with cognitive deﬁcits. Several studies have
suggested that the cerebrovascular mortality rate is higher in
patients with type 2 diabetes (Barrett-Connor and Khaw, 1988;
Lehto et al., 1996). The risk for developing stroke is increased
2- to 5-fold compared to nondiabetic control subjects (Manson
et al., 1991; Stamler et al., 1993). Recently, 5102 patients with
type2diabetesintheUKProspectiveDiabetesStudy(UKPDS)
were analyzed using a newly developed mathematical model.
The results conﬁrmed the higher risk of stroke in type 2 dia-
betes(Kotharietal.,2002).Althoughcerebrovasculardiseaseis
barely mentioned in patients with type 1 diabetes, recent anal-
yses of mortality from 23,000 patients with type 1 diabetes has
shown for the ﬁrst time that cerebrovascular mortality is raised
at all ages in this patient group (Laing et al., 2003). Therefore,
type 1 diabetes is at least as great a risk factor for cerebrovas-
cular mortality as is type 2 diabetes. Based on these reports,
the continuing study of cerebral stroke in diabetes will provide
useful insight into possible underlying mechanisms.
Experimental Studies
Structural Changes
AvarietyofstructuralchangeshasbeendescribedintheCNS
of streptozotocin (STZ)-induced diabetes in rats and Chinese
hamsters (Bestetti and Rossi, 1980, 1982; Garris et al., 1982;
Jakobsenetal.,1987;Luse,1970;Mukaietal.,1980).Structural
alterations of the ventromedial hypothalamus, including accu-
mulation of glycogen, degeneration of neurons, and atrophy of
tanycytes, have been described. Ultrastructural abnormalities,
suchasdilatedandfragmentedendoplasmicreticulum,degran-
ulated ergastoplasm, increased number of microtubuli, myelin
ﬁgures, irregularities in the form of nuclei, and appearance of
chromatin, were described. A signiﬁcant loss of neocortical
neurons occur in STZ-diabetic rats compared to nondiabetic
controlrats(Jakobsenetal.,1987).Inaddition,signiﬁcantstruc-
tural alterations in the BBB were shown in experimental dia-
betic animals (Mooradian, 1997), consistent with the magnetic
resonance imaging ﬁndings in diabetic patients (Starr et al.,
2003).
Neurochemical Changes
The concentration of neurotransmitters appear to be altered
in diabetic brains. A decrease in the norepinephrine (NE) and
serotonin (5-OT) content was shown in the neocortex and cau-
dal segment of the brain stem in alloxan-induced diabetic rats
(Kulikovetal.,1986)andinbrainsofSTZ-induceddiabeticrats
(Trulson et al., 1986). In contrast, an increase in NE concen-
trations in the paraventricular nucleus, lateral hypothalamus,
ventromedial hypothalamus, and suprachiasmatic nucleus and
increased concentrations of NE, dopamine, and serotonin in
the arcuate nucleus have been described in STZ-diabetic rats
(Barber et al., 2003), indicating that the monoaminergic sys-
tem is affected in experimental diabetic animals. In this study,
insulin treatment reversed these changes, suggesting that in-
sulin deﬁciency and/or hyperglycemia may play a role in the
alteration of monoamine neurotransmission.
Electrophysiological Changes
Thelatenciesofauditoryandvisualpotentialswerefoundto
be prolonged in STZ-diabetic rats (Biessels et al., 1999; Rubini
et al., 1992) and BB/W diabetic rats (Chakrabarti et al., 1991;
Sima et al., 1992), indicating impaired CNS conduction ve-
locities in diabetes. In hippocampal slices from STZ-diabetic
rats, long-term potentiation (LTP) induced by 100-Hz stimu-
lation was impaired, whereas long-term depression (LTD) was
enhanced compared with control rats (Biessels et al., 1998;
Gispen and Biessels, 2000; Kamal et al., 2000), indicating that
altered hippocampal synaptic plasticity occurs in type 1 STZ-
diabeticrats.Becausechangesinhippocampalsynapticplastic-
ity in STZ-diabetic rats occur in association with impairments
of spatial learning function (Gispen and Biessels, 2000; Kamal
et al., 2000), these studies provide a mechanism for cognitive
dysfunction in diabetic animals.
Cognitive Functional Changes
Impaired spatial learning and memory have been demon-
strated using the Morris water maze system in various diabetic
animals including BB/W rats, STZ-diabetic rats, STZ-diabetic
mice, and Otsuka Long Evans Tokushima Fatty (OLETF)
rats (Biessels et al., 1998; Flood et al., 1990; Kamal et al.,
2000; Li et al., 2002a, b; Luesse et al., 2001). Multiple cog-
nitive components are involved in this task, such as problem
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representation of the external environments, and storage and
retrieval of relevant information (Bannerman et al., 1995). The
hippocampal LTP and LTD are two forms of neuronal synaptic
plasticity. In young adult STZ-diabetic rats, hippocampal LTP
expression is impaired, whereas LTD expression is enhanced
(Biessels et al., 1996; Kamal et al., 1999). The alterations in
hippocampal synaptic plasticity is associated with defects in
spatial learning and memory as detected by the Morris water
maze (Biessels et al., 1996, 1998). The impaired performance
in the Morris water maze started 10 weeks after the injection
of STZ (Biessels et al., 1998; Kamal et al., 2000) and the de-
gree of LTP impairment correlated with the duration of dia-
betes (Kamal et al., 1999). In diabetic BB/W rats, we failed
to show impaired spatial learning and memory in acutely dia-
betic rats (2-month), whereas signiﬁcant deﬁcits in the Morris
water maze were demonstrated in 8-month diabetic BB/W rats
(Li et al., 2002b). These results suggest that progressive learn-
ing and memory deﬁciencies in type 1 diabetic rats occur in a
duration-related fashion.
Neuronal Loss/Apoptosis in Type 1 Diabetes
A signiﬁcant loss of neocortical neurons occurs in STZ-
diabetic rats (Jakobsen et al., 1987). In the diabetic Chinese
hamster, neuronal death occurs in the arcuate and ventromedial
nuclei(Garris,1984).Thenatureofcelldeathwasnotdeﬁnedin
theseearlystudies,norwasitdeterminedastowhetherneuronal
losswasassociatedwithcognitivedeﬁcits.Inthespontaneously
diabetic BB/Wor rat, neuronal counts of hippocampal pyrami-
dalcellswereperformedinthehippocampalCA1–CA4 regions.
Nosigniﬁcantdifferencesweredemonstratedat2monthsofdi-
abetes.In8-monthdiabeticanimals,therewerea37%and24%
loss of pyramidal cells in CA1 and CA2 regions, respectively,
whereasotherhippocampalregionsshowednon-signiﬁcantde-
creases in neuronal densities (Li et al., 2002b). To exclude the
effect of body weight on neuronal density, we compared 8-
month diabetic rats with weight-matched control rats, which
did not hippocampal neuronal loss. These data suggest that de-
creased neuronal density is not weight related but diabetes du-
rationrelated.Comparisonswithhyperglycemia-andduration-
matched spontaneously type 2 diabetic BBDRZ/Wor rats re-
vealed a much milder but still signiﬁcant neuronal loss of the
hippocampal CA1 region (Li and Sima, unpublished data).
Theabovestudiesindicatethatneuronallossoccursintype1
diabeticanimals.Astothenatureofthisneuronalloss,wehave
proposed that apoptosis might play an important role. Several
invitroandinvivostudiesappeartosupportthisnotion(Lietal.,
2002b, 2003). No apoptotic activity of hippocampal pyramidal
neurons was shown in 2-month diabetic BB/Wor rats, nor was
anycognitivedeﬁcitsdetectedbytheMorriswatermazeproce-
dure,norwasanyneuronallossdetectable.Ontheotherhand,in
8-month diabetic rats, TUNEL-positive neurons, positive DNA
laddering, and increased Bax expression and caspase-3 activ-
ity were evident and associated with decreased neuronal den-
sity and impaired Morris water maze performances (Li et al.,
2002b). Hence, duration-related apoptosis is likely to account
for the neuronal loss and the concomitant emergence of cogni-
tive impairments in the type 1 diabetic BB/Wor rat.
Ischemic Injury in Diabetic Animals
It is well known that diabetes aggravates brain damage in
experimental and clinical stroke subjects. Diabetes accelerates
maturation of neuronal damage, increases infarct volume, and
induces postischemic seizures (Muranyi et al., 2003). A brief
period of 30 minutes’ focal ischemia in normoglycemic rats
leads to brain damage in a delayed fashion: infarction devel-
ops after 3 days and full maturation is reached by 2 weeks
after recirculation (Du et al., 1996). If preischemic hyper-
glycemia exists or in STZ-diabetic rats, the damage is more
severe than that in nondiabetic animals (Muranyi et al., 2003)
andthedamageevolvesfaster:infarctiondevelopsafter2hours
and is matured after 4 to 6 hours after the ischemic insult
(Gisselsson et al., 1999; Li et al., 1998). The mechanisms un-
derlying diabetes-related aggravation of ischemic brain dam-
age are unclear. Apoptosis, or programmed cell death (PCD),
is believed to play an important role in the pathogenesis of
various human disorders including diabetes (Barr and Tomei,
1994; Fadeel et al., 1999; Orrenius, 1995; Thompson, 1995)
and a vast body of studies has shown that apoptosis is as-
sociated with cerebral ischemia and ischemia-reperfusion in-
jury. It has been demonstrated that a large number of neurons
borderingthematuringinfarctexhibitprominentTUNELstain-
ing, and DNA prepared from the penumbral area of ischemic
cortex show internucleosomal fragmentation (Du et al., 1996).
Increased levels of either expression or activities of caspase-3
(Chenetal.,1998;Schulzetal.,1999)andinductionofcaspase-
activated deoxyribonuclease activity (Luo et al., 2002) are de-
tected in ischemic neurons. DNA fragmentation in ischemic
brains has been demonstrated by either gel electrophoresis or
TUNEL staining (Charriaut-Marlangue et al., 1998; Endres
etal.,1998;Lietal.,1995).Astrongcorrelationhasbeenfound
amongcaspase-3activity,TUNELstaining,andtheappearance
of apoptotic neurons (Cao et al., 2001; Charriaut-Marlangue
et al., 1998; Chen et al., 1998; Namura et al., 1998). Further-
more, cytosolic cytochrome c release is markedly enhanced
in both the ischemic focus and the penumbra in STZ-diabetic
rats, together with increased activation of caspase-3 and accel-
erated cleavage of poly-ADP ribose polymerase (PARP) (Du
et al., 1996), all of which suggest that apoptosis plays a role
in the exaggerating effect of diabetes on cerebral ischemic
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FIGURE 1
Possible pathways leading to CNS dysfunction in diabetes.
Recently,theeffectsoflocalischemiaontype1diabeticrats
versus normal control rats were reported (Britton et al., 2003).
A signiﬁcant increase in the number of TUNEL-positive and
caspase-3–positive cell was demonstrated in selected brain re-
gions(hypothalamicpreopticarea,piriformcortex,andparietal
cortex) of STZ-diabetic rats subjected to middle cerebral artery
occlusion for 24 to 48 hours, compared with nonoccluded dia-
betic rats (Britton et al., 2003). Consistent with these ﬁndings,
preliminary data show that the ladder pattern of nucleosomal
DNA fragmentation (ligation mediated–polymerase chain re-
action [LM-PCR]) cannot be detected in unlesioned normal or
STZ-diabetic animals, but is evident in infarcted cortex of di-
abetic rats (Li and Sima, unpublished data). Bax expression is
increased in normal infarcted cortex and is further increased
in infarcted diabetic cortex. These data suggest that diabetes
confers an expansion of stroke via increased apoptotic activity.
In summary, data obtained from experimental type 1 di-
abetic animals show deﬁnite alterations in structure, neuro-
transmitters, electrophysiology, cognitive function, neuronal
density, and apoptotic activity. These results clearly indi-
cate that “diabetic encephalopathy” is an identiﬁable diabetic
complication.
POSSIBLE MECHANISMS
The mechanisms underlying neuronal apoptosis and CNS
dysfunction are not clear. We believe that contributing factors
are insulin deﬁciency with concomitant C-peptide deﬁciency,
as well as hyperglycemia and possibly the aging process itself
(Figure 1).
Insulin/C-peptide Deﬁciency
Insulin plays an important role in regulation of brain
metabolism. Recent studies show that insulin exerts additional
modulatoryrolesonbrainfunctionssuchasfeeding(Gerozissis
et al., 2001; Schwartz et al., 1992), learning, and memory
(Gerozissis et al., 2001; Zhao and Alkon, 2001). In cerebral
stroke, administration of insulin prevents neuronal death (Voll
and Auer, 1991a; Voll and Auer, 1991b) and reduces neuro-
logical disability (LeMay et al., 1988). These neuroprotective
effects of insulin may be associated with restoration of protein
synthesis via increased dephosphorylation of eukaryotic inia-
tion factor 2α (Sullivan et al., 1999). In STZ-diabetic rats, cog-
nitive deﬁcits is partially corrected by insulin (Biessels et al.,
1998; Gradman et al., 1993). In vitro studies also show that
insulin has an antiapoptotic effects (Bertrand et al., 1999; Lee-
Kwon et al., 1998; Li et al., 2003). We have shown that the
insulin receptor is downregulated in the brain of type 1 diabetic
BB/Wor rats (Li et al., 2002b), suggesting that impaired insulin
action caused not only by insulinopenia but also by impaired
insulin receptor expression may play a role in CNS apoptosis
in diabetes.
In addition to insulin deﬁciency, C-peptide deﬁciency has
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FIGURE 2
C-peptide promotes proliferation of SH-SY5Y cells. Maximal stimulatory effect of C-peptide was demonstrated at a
concentration of 3 nM, whereas scrambled C-peptide did not show demonstrate any stimulatory effect on cell proliferation. Data
are expressed as mean ± SD of 3 individual experiments.  P <. 05;   P <. 01;    P <. 005 versus control; P <. 05;
P <. 01 versus 3 nM C-peptide.
complications. C-peptide is a 31–amino acid peptide that is
cleaved from proinsulin during biosynthesis of insulin (Li
et al., 2001; Steiner and Rubenstein, 1997). Recent studies
have shown that C-peptide possesses physiological functions
other than providing structural support for proinsulin cleavage
(WahrenandJohansson,1998;Wahrenetal.,1994,1996;Sima,
2003a, 2003b). In patients with type 1 diabetes, C-peptide im-
proves renal function, reduces urinary albumin excretion and
glomerular ﬁltration, and decreases blood retinal barrier leak-
age(Fernqvist-Forbesetal.,2001;Forstetal.,1998;Johansson
etal.,1992,1996;Zierathetal.,1991,1996).ChronicC-peptide
replacementpreventsfunctionalandstructuralperipheralnerve
changes in type 1 diabetic rat models (Huang et al., 2002;
Ido et al., 1997; Li et al., 1999; Samnegard et al., 2001; Wu
et al., 1996; Zhang et al., 2001; Sima et al., 2001; Pierson et al.,
2003), suggesting that C-peptide deﬁciency is a participating
factor in the causation of type 1 diabetic complications. We
recently showed that administration of C-peptide partially cor-
rectsperturbedinsulin-likegrowthfactor(IGF)activityandpre-
vents the neuronal apoptosis in hippocampus of type 1 diabetic
BB/W rats (Li et al., 2002c), indicating a relationships between
C-peptide deﬁciency, IGF perturbation, and neuronal apopto-
sis. In neuroblastoma SH-SY5Y cells, C-peptide provides a
dose-dependentstimulatoryeffectoncellproliferation,whereas
no effects were evident with the same concentration of scram-
bled C-peptide (Figure 2). In the same in vitro cell cultures,
apoptosis is induced by high concentrations of glucose, mim-
icking hyperglycemia. Apoptosis of SH-SY5Y cells is inhib-
ited by addition of insulin alone, whereas the combination of
insulinandC-peptideshowanenhancedantiapoptoticeffect,as
assessed by prevention of nuclear condensation and shrinkage,
reduction in the number of apoptotic cells, and stimulation of
Bcl2 expression and nuclear factor (NF)-κB (Li et al., 2003).
The inactivated form NF-κB exists in the cytoplasm as a com-
plex consisting of p50, p65, subunits of inhibitor-κB( I κB). On
stimulation, I-κB is phosphorylated and degraded, resulting in
activation and translocation of NF-κB to the nucleus, where it
activates target gene transcription. It is known that NF-κB and
the genes regulated by this transcription factor, such as those
codingfortumornecrosisfactor(TNF)receptor–associatedfac-
tor1(TRAF1),TRAF2,inhibitor-of-apoptosis(IAP)proteinsc-
IAP1andc-IAP2,manganesesuperoxidedismutase(MnSOD),
Bcl2,andBclxL,playimportantrolesintheregulationofapop-
tosis (Aggarwal, 2000; Bours et al., 2000). In the SH-SY5Y
cells grown under elevated glucose concentrations, C-peptide
plus insulin gives rise to a signiﬁcant increase in nuclear NF-
κB staining (Figure 3), suggesting that insulin/C-peptide play
effective antiapoptotic roles via activation and translocation of
NF-κB. In summary, the data obtained from in vitro system are
consistent with the results obtained from experimental diabetesC-PEPTIDE AND CNS COMPLICATIONS IN DIABETES 85
FIGURE 3
The effects of insulin and/or C-peptide on translocation of NF-κB in SH-SY5Y cells incubated in 100 mM glucose. Localization
of NF-κB is shown by immunocytochemistry (top panels), whereas the content of nuclear NF-κB is matched to nuclear staining
with DAPI (bottom panels), bar = 10 µm. Nuclear content of NF-κB was markedly increased when cells were exposed to the
combination of 3 nM C-peptide and 4 nM insulin.
in animals and support the notion that insulin/C-peptide deﬁ-
ciency plays an important role in type 1 diabetes-induced neu-
ronal apoptosis.
IGF System Impairments
Perturbed IGF system has been shown in the CNS of STZ-
diabeticrats.After2weeksofdiabetes,IGF-IImRNAcontentis
signiﬁcantlydecreasedinbrainandspinalcord.Insulinreplace-
ment partially restores IGF-II mRNA levels in cerebral, cortex,
medulla, and spinal cord (Wuarin et al., 1996). We have sys-
temicallyexaminedtheIGFsystem(IGF-1,IGF-II,IGF-IR,and
insulin receptor [IR]) in the BB/Wor model of type 1 diabetes.
Using Western blotting, Northern hybridization, and in situ hy-
bridization, we found signiﬁcant reductions in the expression
of IGF-I, IGF-II, IGF-IR, and IR already in 2-month diabetic
BB/Wor rats, which persisted in 8-month diabetic rats, indicat-
ing that these abnormalities precede the functional cognitive
impairments and the apoptotic neuronal loss in hippocampus
(Li et al., 2002b).
Hyperglycemia
Hyperglycemia causes increased glucose levels in the brain.
Itiswellestablishedthathyperglycemiacausesoxidativestress
viathepolyolpathway,enhancedadvancedglycationendprod-
ucts (AGEs), and increased lipid peroxidation by-products and
imbalances in the generation of reactive oxygen species and
their scavengers (Ceriello et al., 1993; Lipinski, 2001; Mercuri
et al., 2000; Opara, 2002). Oxidative stress is also associated
with cerebral ischemic injury (Kaminski et al., 2002; Love,
1999) and neuronal apoptosis (Gorman et al., 1996; Nicotera
et al., 1997; Sastre et al., 2000). Extreme hyperglycemia also
causes nonketotic hyperosmolar coma, characterized by vol-
ume depletion, altered consciousness, confusion, and, less fre-
quently, neurological deﬁcit in the absence of ketonemia or
acidosis. Hyperosmolar coma is a severe complication of dia-
beteswithahighoverallmortalityrate(Amundsonetal.,1996;
Braaten, 1987; Rolfe et al., 1995; Ting, 2001). It is therefore
likely that hyperglycemia per se may induce apoptotic activi-
ties, preferably via oxidative stress, as indicated by hippocam-
pal apoptosis with neuronal loss in the type 2 hyperinsulinemic
BBDRZ/Wor rat (Li and Sima, unpublished data.
Aging
Aging in developed countries is associated with an in-
creasing prevalence of hypertension, atherosclerotic vascu-
lar diseases, reduced insulin sensitivity, and type 2 diabetes86 Z.-G. LI AND A. A. F. SIMA
(Barbagalloetal.,1997).IntheRotterdamStudy,acommunity-
based prospective cohort study, chronic disorders of the elderly
wereinvestigated.Therelativeriskfordevelopingdementiawas
doubledindiabeticpatients(Ottetal.,1999),suggestingthatdi-
abetes increases the risk of dementia, particularly in the elderly
(Gardonietal.,2002).Itwasrecentlydemonstrated(Terryetal.,
2001)thattheexpressionofIGF-I,IGF-IR,andIRisreducedin
susceptiblehippocampalareasinAlzheimer’sdisease.Wehave
shown that impaired IGF and insulin activities precede the de-
velopment of hippocampal apoptosis in type 1 diabetic BB/W
rats(Lietal.,2002b).ThesimilarityinperturbationsoftheIGF
system suggests that possible common etiological factors may
be present in Alzheimer’s disease and diabetes, two disorders
in which apoptosis has been invoked as a mechanism. How-
ever, other studies have failed to ﬁnd an association between
diabetesandincidentAlzheimer’sdisease(Hassingetal.,2002;
MacKnight et al., 2002). More work is needed to elucidate the
effect of aging on impaired CNS function in diabetes.
CONCLUSION
Diabetes causes impairments in CNS functions. Primary
diabetic encephalopathy is characterized by neurophysiologi-
cal impairments, structural changes, and cognitive deﬁcits. The
mechanisms underlying this CNS dysfunction of diabetes are
not fully elucidated. We propose that insulin/C-peptide deﬁ-
ciency in type 1 diabetes may be one important factor in the
pathogenesis of CNS dysfunctions. It appears that apoptotic
phenomena are contributing factors. However, much work is
still needed to elucidate possible apoptotic pathways and likely
alterations in contraregulatory mechanisms. The increased in-
farct size seen both in diabetic patients and animals follow-
ing cerebral ischemia is likely to be caused by apoptosis. As
to whether these apoptotic mechanisms are the same as those
involved in primary diabetic encephalopathy remain to be
examined.
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